To illustrate, the expression levels of OAS3, a member of the OAS antiviral effector protein family, show similar levels between symptomatic and symptom-free participants in the SARS-CoV-2 negative group, but show different levels in the COVID-19 positive group (Fig. 3). This evidence concerns the gene OAS3 and COVID-19.